STAGING SYSTEMS like that used in Hodgkin's disease are being increasingly applied to haemopoietic neoplasms because of their prognostic value. In myelomatosis Durie & Salmon (1975) have defined 3 stages based on estimates of the total tumour burden. A more direct approach is to ask which combination of features recorded at the time of presentation best predict survival. This is the approach we and others (Costa et al., 1] 973; S.E. Cancer Study Group, 1975; Matzner et al., 1978) have used. Our approach involves the direct correlation of presenting features with survival and has led Us to devise a simple classification procedure based upon 3 factors: renal function (blood urea concentration (BUC) after hydration), anaemia (haemoglobin (Hb) at presentation), and an index of clinical performance status (asymptomatic or minimal symptoms vs restricted activity or confined to bed). This classification was then applied to the 1st and 2nd MRC myelomatosis trials, and confirmed the usefulness of the classification over 5-and 11-year follow-up periods respectively.
PATIENTS AND METHODS
Patienits -with myelomatosis wvere entered through 14 regional centres in the U.K. To be eligible patients must not have been previously treated (except for local radiotherapy or courses of corticosteroids) and must have had at least 2 of the following 3 criteria at presentation:
(ii)
Marrow smears or sections showing plasma-cell infiltration. Skeletal X-rays with definite osteolytic lesions.
A paraprotein in the serum and/or urine. Patients were excluded if they had previously received cytotoxic therapy for any condition, or were over 75 years of age. Patients were treated with various cytotoxic regimens, the details and effects of which are reported elsewhere (MRC, 1980b) . A total of 508 patients were entered into the trial between 9 July 1975 and 4 August 1978. Of these, 5 have been excluded as misdiagnosed, 7 exceeded the age limit of 75, and 4 remain untraced. Records are incomplete in 7 further cases, and do not permit prognostic grouping. This leaves a total of 485 cases for which prognostic factors can be assessed (Table I) . (57%) deaths had occurred. Median survival time is 21 months and 1-and 2-year survival rates are 63% and 46% respectively. All life tables are based on the actuarial method, and significance levels are based on logrank statistics. Relative death rates are defined as the ratio of observed to "expected" deaths, where expected deaths are calculated on the null hypothesis that each death in a given stratum is equally likely to have occurred in any patient at risk at that time (cf. Peto et al., 1976 Peto et al., , 1977 (Tables II and IV) . BUC values were used for grouping because the data were more complete.
Survival curves for the 4 groups of patients whose post-hydration BUC levels were < 8, 8-10, 10-16, > 16 mm are shown in Fig. 1 [Hb] > 115 g/l fare no better than those in the 100-115g/l range. There is also a shallow survival gradient in the 75-100g/l range. The prognostic significance of [Jib] is largely independent of BUC levels below 10 mM (Fig. 3a, b) . Above that level
[Hb] appears to confer little further prognostic information (Fig. 3c) The x2 for performance status after stratification for these 3 groups is 31 6, which is 81.10/ of the uncorrected value. This variable was highly significant in Groups A and C and showed a similar but smaller effect in (hroup B (Table III) . Other factors were found to have lower prognostic value, and for simplicity are not considered for groupings. Based oni these 3 variables, the following grouips have beeni specified: I G0ood prognosis: BUC < 8 mmd (1 d.f.) reflects to some extent the fact that these same data were used to make the classification, though the large sample size and the simple diagnostic criteria make it uinlikely to be greatly inflated. The good, 100 (30) 123 (36) 162 (48) 87 (26) 92 (27) 90 (24) 229 (62) 52 (14) 341 (75) 116 (25) 251 (53) 205 (43) 17 (4) 269 (61) 115 (26) 59 (13) 80 (18) 313 (70) 51 (12) 425 (90) 48 (10) 113 (26) 65 (15) 261 (59) 193 (40) 215 (44) 77 (16) 246 (51) 239 (49) 243 (56) 126 (30) 62 (14) 259 (62) 158 (38) 34 (24) 70 (50) 36 (26) 836 (17) 38 (47) 29 (36) 71 (28) 82 (32) 101 (40) 95 (30) 172 (43) 51 (16) 363 (79) 96 (21) 221 (72) 86 (28) 137 (63) 36 (17) 45 (20) 141 (65) 24 (16) 42 (19) 155 (33) 308 (67) 321 (69) 142 (31) 422 (91) (Durie & Salmon, 1, 975) . It was further shown that the survival of patients was inversely correlated with the estimated total tumour-cell mass. A better separation into goodprognosis groups could be obtained by combining the estimate of total tumourcell mass with an estimate of renal function, impaired renal ftinction being associated with poor prognosis.
Although the work of Salmon & Smith (1970) confirmed by Woodruff et al. (1979) has clearly shown the prognostic importance of their estimate of tumouir-cell mass, it remains possible that, certain properties of tumour cells mav have adverse effects which can be measuired more directly than through an estimate of the tumour-cell mass, as is certainly the case, at least in part, with the factor impairing renal function. We therefore decided to examine empirically the prognostic significance of features recorded at presentation, to see whether it would be possible to select combinations of feattures that would identify patients with good or poor prognosis. The value of such an attempt depends on its ability to pick out good and poor prognosis groups containing a substantial nuimber of patients with markedly different prospects for survival. The "good" and "poor" prognostic groups used in this analysis each picked out 22%/O of the 485 patients, and the probability of survival for 2 years in these groups was 76% and°9 %. By the radiological findings, as used by Salmon, could not be included. Twentyfour per cent of the patients fell in the low-tumour-mass group and 46% in the high-mass group, and the probability of survival for 2 years in these 2 groups was 76% and 33%. Woodruff et al. (1979) also used these groups. They found that 11% of the patients were in the low-tumour-mass group and 55% in the high-mass group with 2-year survival probabilities of 85% and 18%. If only patients treated with melphalan or cyclophosphamide are included, the group sizes change to 13% and 50%0 respectively. It is apparent that their high-tumour-mass group contains patients whom we would classify into the intermediate prognosis group.
Thus, the discriminating power of the groups we have chosen as a result of empirical analysis compares favourably with Salmon's groupings based on an estimate of the tumour-cell mass. As shown in Figs 6 & 7, the discriminating power of our empirical groups holds when they are applied to the 1st and 2nd MRC Trials, with a much longer follow-up than the 3rd trial.
In practice, the prognostic groups are easy to apply because they are based on readily available information and there is little likelihood of error in recording the clinical performance status, or of technical unreliability in the measurement of [Hb] or BUC.
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